AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
14.6 C
New York
Thursday, October 22, 2026

Tag: safety profile

newsFORsourcecompanycontentinformation1releasesmarket

BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal TherapySHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for...

CARsgen Therapeutics Announces NDA Acceptance of Satri-cel by China’s NMPA

SHANGHAI, June 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

ProZenith Ingredients Researched: The Science Behind the Popular Formula

Plant-Based Ingredients, Scientific Research, and Mineral Synergy Come Together in This Modern Approach to Natural Weight Support 
Plant-Based Ingredients, Scientific Research, and Mineral Synergy Come Together in This Modern Approach to Natural Weight Support

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer...

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer...

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /CNW/ -- Equity Insider News Commentary – Rising rates of cancer...

SRPT STOCK LOSS: Sarepta Therapeutics, Inc. Shareholders are Alerted of Ongoing Securities Fraud Investigation — Contact BFA Law (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud investigation.

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson’s Care.” The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSafety profile

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers